Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering

Abstract:
WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012. A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000. Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer. WestPark Capital, Inc. acted as placement agent for the offering.

WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering

Los Angeles, CA | Posted on January 20th, 2012

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by Confidential Private Placement Memorandum. Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

####

About WestPark Capital, Inc.
WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them. WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at . Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a new generation of diagnostic and therapeutic drugs based on a new family of nano-biopolymers. Arrogene was founded in 2007 to commercialize a new cancer targeting technology and a proprietary molecular delivery platform that interferes with cancer targets to inhibit and finally eradicate tumor progression. Additional information about Arrogene is available at www.arrogene.com.

For more information, please click here

Contacts:
WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Biosensors: Distance makes the signal grow stronger March 1st, 2017

Smart multi-layered magnetic material acts as an electric switch: New study reveals characteristic of islands of magnetic metals between vacuum gaps, displaying tunnelling electric current March 1st, 2017

Bioinspired process makes materials light, robust, programmable at nano- to macro-scale: Ultralight web of silk nano fibers withstands load 4,000 times its weight February 28th, 2017

NovAliX Turns to High-Resolution Cryo-Transmission Electron Microscopy for Pre-Clinical Drug Discovery Research: Thermo Fisher Scientificís Cryo-TEM provides critical information for small molecule and biologic drug discovery February 28th, 2017

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Nanomedicine

Biosensors: Distance makes the signal grow stronger March 1st, 2017

NovAliX Turns to High-Resolution Cryo-Transmission Electron Microscopy for Pre-Clinical Drug Discovery Research: Thermo Fisher Scientificís Cryo-TEM provides critical information for small molecule and biologic drug discovery February 28th, 2017

New nano approach could cut dose of leading HIV treatment in half February 24th, 2017

Atomic force imaging used to study nematodes: KFU bionanotechnology lab (head - Dr. Rawil Fakhrullin) has obtained 3-D images of nematodes' cuticles February 23rd, 2017

Announcements

Biosensors: Distance makes the signal grow stronger March 1st, 2017

Smart multi-layered magnetic material acts as an electric switch: New study reveals characteristic of islands of magnetic metals between vacuum gaps, displaying tunnelling electric current March 1st, 2017

Bioinspired process makes materials light, robust, programmable at nano- to macro-scale: Ultralight web of silk nano fibers withstands load 4,000 times its weight February 28th, 2017

NovAliX Turns to High-Resolution Cryo-Transmission Electron Microscopy for Pre-Clinical Drug Discovery Research: Thermo Fisher Scientificís Cryo-TEM provides critical information for small molecule and biologic drug discovery February 28th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project